Stone Ridge Asset Management LLC increased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 27.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,577 shares of the company’s stock after acquiring an additional 763 shares during the period. Stone Ridge Asset Management LLC’s holdings in Omnicell were worth $219,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of OMCL. Bronfman E.L. Rothschild L.P. boosted its holdings in shares of Omnicell by 451.8% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 618 shares of the company’s stock worth $38,000 after purchasing an additional 506 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Omnicell by 7.9% during the 4th quarter. Geode Capital Management LLC now owns 442,184 shares of the company’s stock worth $27,079,000 after purchasing an additional 32,512 shares during the last quarter. Magnus Financial Group LLC acquired a new position in shares of Omnicell during the 4th quarter worth approximately $217,000. California State Teachers Retirement System raised its position in shares of Omnicell by 2.4% during the 4th quarter. California State Teachers Retirement System now owns 60,708 shares of the company’s stock valued at $3,718,000 after buying an additional 1,438 shares during the period. Finally, Brown Advisory Inc. raised its position in shares of Omnicell by 29.2% during the 4th quarter. Brown Advisory Inc. now owns 11,619 shares of the company’s stock valued at $712,000 after buying an additional 2,627 shares during the period. Hedge funds and other institutional investors own 98.62% of the company’s stock.
Several research firms have recently commented on OMCL. Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “sell” rating in a research report on Monday, March 25th. BidaskClub lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Wednesday, March 27th. ValuEngine raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. Finally, Dougherty & Co lifted their price target on shares of Omnicell from $78.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, March 7th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Omnicell has a consensus rating of “Buy” and a consensus target price of $76.56.
Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 7th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.16. The company had revenue of $211.75 million for the quarter, compared to analyst estimates of $215.41 million. Omnicell had a return on equity of 9.31% and a net margin of 4.79%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.55 earnings per share. Analysts forecast that Omnicell, Inc. will post 1.83 earnings per share for the current year.
In other Omnicell news, EVP Dan S. Johnston sold 8,902 shares of the business’s stock in a transaction that occurred on Monday, January 14th. The stock was sold at an average price of $64.16, for a total value of $571,152.32. Following the sale, the executive vice president now owns 33,216 shares of the company’s stock, valued at $2,131,138.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Nhat H. Ngo sold 1,823 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $82.33, for a total value of $150,087.59. Following the completion of the sale, the executive vice president now directly owns 37,569 shares in the company, valued at approximately $3,093,055.77. The disclosure for this sale can be found here. In the last three months, insiders sold 89,674 shares of company stock worth $7,294,010. 3.71% of the stock is owned by corporate insiders.
Omnicell Company Profile
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Read More: Understanding Analyst Recommendations
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.